CMEtracker Log in | Veritas Institute for Medical Education, Inc. | Thursday, October 02, 2014  


Academic Debates: Patients With Normal ALT and High Viral Load Are at High Risk for Liver-Related Complications and Should/Should Not Be Offered HBV Therapy

Academic Debates: Will the Standard of Care for Hepatitis C Genotype 1 Be an All-Oral Interferon-Free Therapy by 2015? PRO vs CON


2 CME/CE-Certified On-Demand Webinars


Release Date: May 1, 2013
Expiration Date: : May 31, 2014
Estimated time to complete each activity: 60 minutes

Sponsorship and Support
Jointly sponsored by Veritas Institute for Medical Education, Inc. and the American Liver Foundation. Supported by educational grants from AbbVie, Inc. and Vertex Pharmaceuticals Incorporated.

Statement of Need
The purpose of the 2013 Academic Debates is to examine controversial issues within the management of liver disease, and allow medical professionals to address current and best treatment practices. These videotaped presentations derived from the debates on HBV and HCV offer you the current and best practices, new research in hepatology, and the evidence necessary to evaluate two distinct options. The first, pertaining to HBV, is whether the patient with normal ALT levels and high viral load should or should not be treated. The second, pertaining to HCV, explores the status of IFN-free regimens and developments in treatment, as well as appropriate patient selection, understanding of treatment success probability, and potential side effects.

Distinguished Faculty
Moderator
Michael R. Charlton, MD

Mayo Clinic
Rochester, Minnesota

Academic Debates: Patients With Normal ALT and High Viral Load Are at High Risk for Liver-Related Complications and Should/Should Not Be Offered HBV Therapy
Mentor - Pro
Anna Suk-Fong Lok, MD, FRCP

University of Michigan Health System
Ann Arbor, Michigan

Jessica Mellinger, MD
University of Michigan Hospitals and Health Centers
Ann Arbor, Michigan

Reena Salgia, MD
University of Michigan Hospitals and Health Centers
Ann Arbor, Michigan

Mentor ─ Con
Bashar Attar, MD, PhD
John H. Stroger, Jr Hospital of Cook County
Chicago, Illinois

Andrew Kim, MD
John H. Stroger, Jr Hospital of Cook County
Chicago, Illinois

Neil Sheth, MD
John H. Stroger, Jr Hospital of Cook County
Chicago, Illinois

Academic Debates: Will the Standard of Care for Hepatitis C Genotype 1 Be an All-Oral Interferon-Free Therapy by 2015? PRO vs CON

Mentor - Pro
Sheila Eswaran, MD, MS

Rush University Medical Center
Chicago, Illinois

Shifali Arora, MD
Rush University Medical Center
Chicago, Illinois

Suhail Salem, MD
Rush University Medical Center
Chicago, Illinois

Mentor ─ Con
Natasha Von Roenn, MD
Loyola University Health System

Ross A. Sage, MD
Loyola University Medical Center
Chicago, Illinois

Samad Soudagar, MD
Loyola University Medical Center
Chicago, Illinois

Intended Audience
The intended audience for this activity includes hepatologists, gastroenterologists, infectious disease specialists, physician assistants, and nurse practitioners involved in the care of patients with hepatitis B virus and/or hepatitis C virus infection.

Learning Objectives HBV
Academic Debates: Patients With Normal ALT and High Viral Load Are at High Risk for Liver-Related Complications and Should/Should Not Be Offered HBV Therapy

  • Appraise current guideline recommendations for initiating treatment in patients with normal ALT and a high HBV viral load
  • Analyze the increased risk for liver-related complications in patients with normal ALT and a high HBV viral load when making treatment decisions

Learning Objectives HCV
Academic Debates: Will the Standard of Care for Hepatitis C Genotype 1 Be an All-Oral Interferon-Free Therapy by 2015? PRO vs CON

  • Identify patients with chronic HCV infection who, based on clinical evaluation, would benefit from timely treatment intervention with current triple therapy regimens
  • Recognize patients with chronic HCV infection for whom the deferral of treatment might be indicated until newer therapies are available

Accreditation Statement/Designation of Credit Statements
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Veritas Institute for Medical Education, Inc. and the American Liver Foundation. Veritas Institute for Medical Education, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

Physicians and Physician Assistants
Veritas Institute for Medical Education, Inc. designates each enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioners
Veritas Institute for Medical Education, Inc. approved as a provider for nurse practitioner continuing education by the American Association of Nurse Practitioners: AANP Provider Number 040309. These programs have been approved for 1.0 contact hour of continuing education (which includes 1.0 hour of pharmacology).

Faculty and Planner Disclosure
In accordance with the ACCME’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Disclosures are as follows:

Shifali Arora, MD: Has nothing to disclose
Bashar Attar, MD, PhD: Has nothing to disclose
Michael R. Charlton, MD: Biotest (consultant); Bristol Myers Squibb (grant/research support); Gilead (grant/research support); Norgine (consultant); Novartis (grant/research support); Vertex (grant/research support)
Sheila Eswaran, MD, MS: Has nothing to disclose
Andrew Kim, MD: Has nothing to disclose
Anna Suk-Fong Lok, MD, FRCP: Bristol Myers Squibb (grant/research support); Gilead (consultant, grant/research support); GlaxoSmithKline (consultant); Merck (grant/research support); Roche (consultant)
Jessica Mellinger, MD: Has nothing to disclose
Ross A. Sage, MD: Has nothing to disclose
Suhail Salem, MD: Has nothing to disclose
Reena Salgia, MD: Has nothing to disclose
Neil Sheth, MD: Has nothing to disclose
Samad Soudagar, MD: Has nothing to disclose
Natasha Von Roenn, MD: Has nothing to disclose

The staffs of Veritas Institute for Medical Education, Inc., and the American Liver Foundation have nothing to disclose.

Off-Label/Investigational Uses Of Drugs
Participants are advised that this CME/CE activity will contain references to unlabeled/unapproved/investigational uses of drugs to treat patients with liver disease.

Disclaimer
The opinions expressed in this activity are those of the presenters and do not necessarily reflect those of Veritas Institute for Medical Education, Inc., the American Liver Foundation, AbbVie, Inc. or Vertex Pharmaceuticals Incorporated. Please consult the appropriate package insert for full prescribing information on all drug therapies discussed.

Method of Participation

  • View the Webinars
  • Complete and pass the Posttest by answering both questions correctly per activity
  • Complete and submit the CME/CE Activity Evaluation and Request for Credit Form
  • You will receive your statement of credit immediately
  • Alternatively, you may fax or mail your form to Veritas Institute for Medical Education, Inc. at the number or address listed. You will receive your CME/CE certificate within 2 weeks.
This activity is provided free of charge to participants.


Click here if you want to review activity(ies) and/or retake test(s) again.



Copyright © 2014 Veritas Institute for Medical Education, Inc. All rights reserved.
Use of this site is subject to the Internet Site Legal Notices and Disclaimers and Privacy Policy.